In the news

As lifespans grow longer, targeted medical technology can help people live better, healthier lives—with fewer pills.

Dr. Janar Sathananthan, president, Interventional Cardiology, discusses the FRACTURE IDE trial, which met its primary endpoints for the SEISMIQ™ 4CE Coronary IVL Catheter in severely calcified coronary disease. The result underscores Boston Scientific’s broader intravascular lithotripsy commercialization strategy and differentiated cardiology solutions.

Karen Carlson’s incontinence kept her housebound for years despite various failed treatments. The Axonics™ Sacral Neuromodulation Therapy helped relieve her symptoms, restoring her active life.

This sponsored article explores how physicians are helping patients living with atrial fibrillation address two health issues at the same time: irregular heart rhythms and stroke risk.

The CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line option for stroke risk reduction met all primary and secondary endpoints and demonstrated superior bleeding risk reduction and similar efficacy of the WATCHMAN FLX device compared to oral anticoagulants in a broad population of patients with non-valvular atrial fibrillation.

Learn how findings from the HI-PEITHO trial highlight a major advance in the treatment of immediate-risk pulmonary embolism, with ultrasound-assisted, catheter-directed thrombolysis using the EKOS™ Endovascular System reducing early complications without increasing major bleeding.

The VAPEUR clinical trial compared Rezūm™ Water Vapor Therapy to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in sexually active men. Key findings from the study demonstrate that Rezūm Therapy provides superior BPH symptom relief versus combination therapy while preserving sexual function.

Driven by an improved safety profile, strong patient demand and more predictable procedures, health systems are increasing investment in pulsed field ablation (PFA)—including technology like the FARAPULSE™ PFA Platform—to treat atrial fibrillation.

Read how Boston Scientific designed its latest employee campus with an intentional focus on collaboration for rapid innovation in this interview with Stephanie Board, group vice president, Research & Development, Interventional Cardiology & Vascular Therapies.

Learn how Boston Scientific consistently achieved superior results while minimizing distressing organizational transformations by creating and continually cultivating the business equivalent of a thriving, adaptive biological ecosystem.

Kyra Williams shares her experience with endoscopic sleeve gastroplasty, a minimally invasive weight loss procedure that helped support her goals.

AI adoption is much bigger than a workplace tech initiative – it’s a change management challenge. That’s why, writes SVP of enterprise services and digital officer Jodi Euerle Eddy, “if your IT department aims to create an AI-enabled workforce, a close IT and HR partnership is essential.”

Read how the AGENT™ Drug Coated Balloon — now available in the U.S. — addresses a critical unmet need for in-stent restenosis (ISR) treatment, using tech that represents a “quantum leap” forward.

A recent survey highlights that women are seeking new ways to lose weight, as Boston Scientific launches Endura Weight Loss Solutions to increase awareness of minimally invasive weight loss procedures.

Ronald Morton, M.D., chief medical officer, Urology, Boston Scientific sheds light on two taboo topics affecting millions of men: erectile dysfunction (ED) and stress urinary incontinence (SUI).

At STAT’s AI-focused Breakthrough Summit West, Ken Stein, MD, senior vice president and global chief medical officer, shares how artificial intelligence is helping cardiologists make the leap from available insights to actionable ones.

At DeviceTalks Minnesota, Ken Stein, MD, senior vice president and global chief medical officer, outlines the steps Boston Scientific takes to evaluate a market, choose a development approach and establish the groundwork for adoption.

CEO Mike Mahoney shares lessons learned over his career that helped him shape Boston Scientific's winning culture and drive the company’s growth.

Lisa Considine, senior vice president of global talent, describes the professional development opportunities offered by Boston Scientific to early career talent that supports the company’s top ranking on Forbes’ list of America’s Best Employers for New Grads.

Dr. Michael R. Jaff, chief medical officer, Peripheral Interventions, discusses new data supporting the Eluvia™ Drug-Eluting Vascular Stent System presented at the Charing Cross Symposium. The article also explores how design elements of the device contribute to long-term outcomes in treating peripheral artery disease and future opportunities for innovation in drug-device combination therapies.

Ken Stein, MD, senior vice president and global chief medical officer, highlights how AI is being applied today to deliver more proactive, personalized and precise medical

Jodi Eddy, chief information and digital officer, explains the importance of ensuring IT teams at rapidly growing organizations are at the table when key initiatives are being discussed.

Boston Scientific has approximately doubled its Minnesota workforce in the last 15 years. It has become the largest employer in both Maple Grove and Arden Hills. And it’s not done expanding.

Jodi Eddy, chief information and digital officer, unpacks three aspects of corporate culture that are separating leaders from the pack in the global pursuit of generative AI adoption.

Dr. Brad Sutton, chief medical officer, Atrial Fibrillation Solutions, discusses two of the latest FARAPULSE™ Pulsed Field Ablation System innovations and how the acquisition of Cortex, Inc. will fit into the Boston Scientific Electrophysiology portfolio.

In an interview with CNBC’s Jim Cramer, CEO Mike Mahoney shares how breakthrough products, an active venture portfolio and strategic acquisitions continue to drive high business performance.

Ken Stein, MD, senior vice president and global chief medical officer, discuss health inequities and Boston Scientific's work to improve access to care for underserved populations.

Boston Scientific presented a study at the 23rd American Society of Regional Anesthesia and Pain Medicine Meeting that demonstrates Fast-Acting Sub-Perception Therapy (FAST), with the WaveWriter spinal cord stimulation systems, as a breakthrough solution that significantly reduces chronic pain and improves patient outcomes with high satisfaction for up to 12 months, and no increase in opioid use during the primary endpoint interval.

Jodi Euerle Eddy, chief information and digital officer, shares the importance of interdepartmental collaboration in creating a culture of innovation that supports the investment, deployment and successful adoption of new technology.

As the number of people diagnosed with atrial fibrillation (AF) rises around the world, Ken Stein, MD, senior vice president and global chief medical officer and Nick Spadea-Annello, global president, Electrophysiology, along with industry experts, offer the Star Tribune perspective on the paradigm shift to pulsed field ablation for the treatment of AF, the explosive growth of the FARAPULSE™ Pulsed Field Ablation System, the competitive innovation race and the future of cardiac care.

Through interviews with senior executives and industry analysts, The Boston Globe explores how the combination of Boston Scientific’s acquisition strategy, in-house R&D and investment portfolio position the company for long-term success.

Boston Scientific has completed its $1.18 billion acquisition of Silk Road Medical, adding the TCAR stroke-prevention platform to its vascular portfolio to enhance patient outcomes and expand its minimally invasive treatment options.

Dr. Ken Stein, senior vice president and global chief medical officer, illustrates AI’s potential to enable more personalized care, especially through wearable devices and home-based health monitoring.

Camille Chang Gilmore, vice president of human resources and global chief diversity officer, shares our commitment to developing a workforce that is reflective of the patients and communities we serve, inclusive of individuals with disabilities.

Samir Bhattacharyya, vice president of global value and marketing for Health Economics & Market Access, Urology, discusses the impact erectile dysfunction (ED) can have on work productivity and mental health and the importance of ensuring ED treatment coverage is available to employees.

As the number of people living with conditions like prostate cancer or kidney stones increases, there is also a serious shortage of urologists to meet these growing patient needs. Senior vice president and president of Urology Meghan Scanlon discusses the importance of supporting the next generation of urologists to meet the evolving demands of this field.

Jodi Eddy, senior vice president and chief information and digital officer, shares how she transformed the IT organization and empowered her team to support the company’s strategic priorities.

The Boston Scientific Intracept™ Intraosseous Nerve Ablation System helps transform the lives of people who are living with chronic pain.

In an interview with CNBC’s Jim Cramer, CEO Mike Mahoney shares Boston Scientific’s strong track record of consistently delivering great results and what we’re looking forward to next.

Since 2008, Boston Scientific has worked closely with Boston Health Care for the Homeless Program to help close gaps in medical and social services for those living in shelters or on streets.

Dr. Ken Stein, SVP and chief global medical officer, discusses the tremendous opportunities to use digital capabilities in medtech.

Dr. Janar Sathananthan, chief medical officer, Interventional Cardiology Therapies, discusses a new treatment option in the U.S. for patients with coronary artery disease who experience in-stent restenosis.

Wendy Carruthers, executive vice president of human resources, describes hybrid work as the best of both worlds with benefits for employees and employers alike.

Boston Scientific announced that it has entered into a definitive agreement to acquire Silk Road Medical, Inc., a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR).

Boston Scientific announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System, the first modular cardiac rhythm management (CRM) system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Leadless Pacemaker (LP).

A presentation from WIRED Health 2024 discusses how Boston Scientific is advancing technologies to transform chronic pain care today and in the future.

The first coronary drug-coated balloon to be FDA-approved in the U.S., the Boston Scientific AGENT^TM Drug-Coated Balloon addresses a clinical unmet need by treating and preventing reoccurrence of in-stent restenosis in patients with coronary artery disease.

Boston Scientific shares how real-world data can help optimize physician decision making when treating patients with pulmonary embolism (PE).

Lisa Considine, vice president of human resources, and Adriana Gonzalez, director of global supply chain, share how Boston Scientific’s on-site day care in Marlborough, MA provides support and flexibility for employees while reinforcing an organizational culture of caring.

Next generation spinal cord stimulation devices, including Boston Scientific’s WaveWriter Alpha^TM SCS System, are providing relief to people living with diabetic peripheral neuropathy who are unresponsive to drugs or experience side effects.